INFLARX NV IFRX
COM · Common Stock · CUSIP N44821101
- SectorHealth care
- IndustryPharmaceutical Preparations
- FilingsSEC EDGAR
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Shares outstanding: 26.1m as of 2019-12-31, from the company's own SEC filing; the percentage can still exceed 100%: lent-out shares are counted by the lender and the buyer, and some reports overlap without saying so. Implied quarter-end price ≈ $3.96.
Major shareholders (over 5%)
Anyone who owns more than 5% of a class of the company's shares has to say so: on Schedule 13D if they may try to influence or control the company, on 13G if they're a passive investor, and update it as the stake changes. Each holder's latest filing, from 19 Dec 2024 on; percentages are of the share class, as the holder worked them out.
| Holder | Stake |
|---|---|
| MONTANOVA CAPITAL, LLC 13G · passive investor +3.9 pts · filed 2026-08-14 | 15.6% |
| TCG Crossover GP III, LLC 13G · passive investor new · filed 2026-05-12 | 9.8% |
| Sirenia Capital Management LP 13G · institution new · filed 2026-08-14 | 6.1% |
| FMR LLC 13G · institution new · filed 2026-08-06 | 5.5% |
| Commodore Capital LP 13G · passive investor new · filed 2026-08-17 | 5.1% |
| Farallon Capital Partners, L.P. 13G · passive investor new · filed 2026-05-14 | 5.1% |
Fell to 5% or below in the last year: FARALLON CAPITAL MANAGEMENT, L.L.C. (2.3%, 2026-08-14; now reported by Farallon Capital Partners, L.P.)
Insider purchases and sales in Q4 2019
Shares bought or sold by the company's own officers, directors and 10% owners, in the open market or privately, as they reported to the SEC on Form 4 (due within two business days of the trade). Grants, option exercises, shares withheld for tax and gifts aren't included.
None reported in Q4 2019.
Holders, Q4 2019
| Manager | Shares | Change |
|---|---|---|
| BAKER BROS. ADVISORS LP 0.04% of their portfolio | 1.8m $7.0m | — |
| MORGAN STANLEY 0.00% of their portfolio | 902.4k $3.6m | — |
| FNY Investment Advisers, LLC 0.62% of their portfolio | 500.0k $2.0m | — |
| Ikarian Capital, LLC 1.31% of their portfolio | 359.1k $1.4m | — |
| Eversept Partners, LP 0.27% of their portfolio | 334.6k $1.3m | — |
| SPHERA FUNDS MANAGEMENT LTD. 0.17% of their portfolio | 330.0k $1.3m | — |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC 0.31% of their portfolio | 220.0k $869.0k | — |
| GEODE CAPITAL MANAGEMENT, LLC 0.00% of their portfolio | 175.6k $694.0k | — |
| GOLDMAN SACHS GROUP INC 0.00% of their portfolio | 165.9k $657.0k | — |
| MILLENNIUM MANAGEMENT LLC 0.00% of their portfolio | 120.1k $475.0k | — |
| TWO SIGMA ADVISERS, LP 0.00% of their portfolio | 110.5k $438.0k | — |
| CITADEL ADVISORS LLC 0.00% of their portfolio | 105.8k $419.0k | — |
| JPMORGAN CHASE & CO 0.00% of their portfolio | 62.5k $247.0k | — |
| BOOTHBAY FUND MANAGEMENT, LLC 0.03% of their portfolio | 60.1k $238.0k | — |
| BARCLAYS PLC 0.00% of their portfolio | 50.0k $198.0k | — |
| OXFORD ASSET MANAGEMENT LLP 0.00% of their portfolio | 45.1k $179.0k | — |
| Leap Investments LP 0.06% of their portfolio | 34.9k $138.0k | — |
| BlackRock Inc. 0.00% of their portfolio | 11.8k $47.0k | — |
| Tower Research Capital LLC (TRC) 0.00% of their portfolio | 10.2k $41.0k | — |
| FMR LLC 0.00% of their portfolio | 17 $0 | — |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. 0.00% of their portfolio | 0 $0 | — |